Brain Targeted Nanocarriers: A Revolutionary Approach for Treating Neurodegenerative Disorders

Neurodegenerative disorders, which include Alzheimer's, Parkinson's, and Huntington's, pose a significant worldwide health concern due to their gradual loss of neurons and cognitive impairment. The impermeability of the blood-brain barrier (BBB), the quick metabolism of medications, and non-specific delivery make traditional treatment approaches ineffective. Because they allow for site-specific drug administration, improve BBB penetration, and increase therapeutic efficacy while lowering systemic toxicity, brain-targeted nanocarriers provide a ground-breaking option. The techniques based on nanocarriers for the targeted therapy of neurodegenerative illnesses are thoroughly examined in this study. Current clinical uses, targeting ligands, surface changes, therapeutic payload types, administration methods, design considerations, and emerging developments are all covered. Active targeting technologies, such as nanoparticles modified with peptides and transferrins, are given particular attention. Clinical studies, regulatory obstacles, and the potential of gene-based nanotherapeutics are also highlighted in the study, providing fresh hope for the treatment of complicated CNS illnesses.